Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 20/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11519128 | 0.78 | FDPS (0.61) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL11518735 | 0.76 | FDPS (0.58) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL10403160 | 0.75 | FDPS (0.47) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL28434632 | 0.74 | FDPS (0.66) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| SCHEMBL277292 | 0.73 | CYP2C19 (0.32) | — | |
| SCHEMBL4099176 | 0.72 | FDPS (0.67) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| SCHEMBL140141 | 0.72 | FDPS (0.38) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL11518533 | 0.72 | FDPS (0.52) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL8048683 | 0.71 | FDPS (0.47) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL140140 | 0.71 | FDPS (0.39) | FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696427-B1 | ADMINISTERING PHOSPHORUS COMPOUNDS SUCH AS AMINO-HYDROXY-METHYLIDENE-BISPHOSPHONIC ACID, TO DEACTIVATE LYMPHOCYTES AND AS VIRICIDES, BACTERICIDES, FUNGICIDES OR PARASITICIDES | JOMAA PHARMAKA GMBH (DE) | 2004-02-24 | — | — | US | claimed |
| EP-1140113-B1 | USE OF BISPHOSPHONATES FOR THE PREVENTION AND TREATMENT OF INFECTIOUS PROCESSES | BIOAGENCY AG (DE) | 2003-11-05 | — | — | EP | claimed |
| US-20060040899-A1 | Medicaments containing bisphosphonic acids and derivatives thereof for preventing and treating diseases and allergies | JOMAA HASSAN | 2006-02-23 | — | — | US | disclosed |
| US-6696427-B1 | ADMINISTERING PHOSPHORUS COMPOUNDS SUCH AS AMINO-HYDROXY-METHYLIDENE-BISPHOSPHONIC ACID, TO DEACTIVATE LYMPHOCYTES AND AS VIRICIDES, BACTERICIDES, FUNGICIDES OR PARASITICIDES | JOMAA PHARMAKA GMBH (DE) | 2004-02-24 | — | — | US | disclosed |
| EP-0563096-B1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | LEIRAS OY (FI) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040899-A1 | Medicaments containing bisphosphonic acids and derivatives thereof for preventing and treating diseases and allergies | ENPP2, BPGM, HRH2 | FDPS 454/4885GGPS1 216/4885PDE3A 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.